KIMBERLY MARSH: Open Payments
NPI 1134634520 · WORCESTER, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,300 in 52 payments from 16 companies in 2025. Trend: 2023 $186 · 2024 $936 · 2025 $1,300
Food & beverage: $1,300
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 14 | $286 |
| Lundbeck LLC | 7 | $274 |
| SK Life Science, Inc. | 6 | $158 |
| Biogen, Inc. | 4 | $79 |
| Neurocrine BioSciences, Inc. | 3 | $68 |
| Lilly USA, LLC | 3 | $64 |
| Merz Pharmaceuticals, LLC | 2 | $64 |
| ARGENX US, INC. | 2 | $51 |
| Amneal Pharmaceuticals LLC | 2 | $47 |
| Teva Pharmaceuticals USA, Inc. | 2 | $46 |
Products named: VYEPTI, UBRELVY, QULIPTA, INGREZZA, Xeomin, VYVGART, VRAYLAR, CREXONT.
Industry payments across MA — which companies pay providers there.
